Literature DB >> 21665938

Fibroblast growth factor receptor mediates fibroblast-dependent growth in EMMPRIN-depleted head and neck cancer tumor cells.

Zhiyong Liu1, Yolanda E Hartman, Jason M Warram, Joseph A Knowles, Larissa Sweeny, Tong Zhou, Eben L Rosenthal.   

Abstract

Head and neck squamous cell carcinoma tumors (HNSCC) contain a dense fibrous stroma which is known to promote tumor growth, although the mechanism of stroma-mediated growth remains unclear. As dysplastic mucosal epithelium progresses to cancer, there is incremental overexpression of extracellular matrix metalloprotease inducer (EMMPRIN) which is associated with tumor growth and metastasis. Here, we present evidence that gain of EMMPRIN expression allows tumor growth to be less dependent on fibroblasts by modulating fibroblast growth factor receptor-2 (FGFR2) signaling. We show that silencing EMMPRIN in FaDu and SCC-5 HNSCC cell lines inhibits cell growth, but when EMMPRIN-silenced tumor cells were cocultured with fibroblasts or inoculated with fibroblasts into severe combined immunodeficient mice, the growth inhibition by silencing EMMPRIN was blunted by the presence of fibroblasts. Coculture experiments showed fibroblast-dependent tumor cell growth occurred via a paracrine signaling. Analysis of tumor gene expression revealed expression of FGFR2 was inversely related to EMMPRIN expression. To determine the role of FGFR2 signaling in EMMPRIN-silenced tumor cells, ligands and inhibitors of FGFR2 were assessed. Both FGF1 and FGF2 enhanced tumor growth in EMMPRIN-silenced cells compared with control vector-transfected cells, whereas inhibition of FGFR2 with blocking antibody or with a synthetic inhibitor (PD173074) inhibited tumor cell growth in fibroblast coculture, suggesting the importance of FGFR2 signaling in fibroblast-mediated tumor growth. Analysis of xenografted tumors revealed that EMMPRIN-silenced tumors had a larger stromal compartment compared with control. Taken together, these results suggest that EMMPRIN acquired during tumor progression promotes fibroblast-independent tumor growth.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21665938      PMCID: PMC3157557          DOI: 10.1158/1541-7786.MCR-11-0043

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  45 in total

1.  Expression of emmprin by oral squamous cell carcinoma.

Authors:  L C Bordador; X Li; B Toole; B Chen; J Regezi; L Zardi; Y Hu; D M Ramos
Journal:  Int J Cancer       Date:  2000-02-01       Impact factor: 7.396

2.  Basigin (CD147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts.

Authors:  Takuro Kanekura; Xiang Chen; Tamotsu Kanzaki
Journal:  Int J Cancer       Date:  2002-06-01       Impact factor: 7.396

Review 3.  Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.

Authors:  S Zucker; J Cao; W T Chen
Journal:  Oncogene       Date:  2000-12-27       Impact factor: 9.867

4.  Current evidence on the relationship between three polymorphisms in the FGFR2 gene and breast cancer risk: a meta-analysis.

Authors:  Jian Zhang; Li-Xin Qiu; Zhong-Hua Wang; Shiang-Jiin Leaw; Bi-Yun Wang; Jia-Lei Wang; Zhi-Gang Cao; Jia-Li Gao; Xi-Chun Hu
Journal:  Breast Cancer Res Treat       Date:  2010-03-19       Impact factor: 4.872

5.  EMMPRIN regulates the canonical Wnt/beta-catenin signaling pathway, a potential role in accelerating lung tumorigenesis.

Authors:  S S Sidhu; R Nawroth; M Retz; H Lemjabbar-Alaoui; V Dasari; C Basbaum
Journal:  Oncogene       Date:  2010-05-31       Impact factor: 9.867

6.  Breast cancer cell-derived EMMPRIN stimulates fibroblast MMP2 release through a phospholipase A(2) and 5-lipoxygenase catalyzed pathway.

Authors:  Paul M Taylor; Richard J Woodfield; Matthew N Hodgkin; Trevor R Pettitt; Ashley Martin; David J Kerr; Michael J O Wakelam
Journal:  Oncogene       Date:  2002-08-22       Impact factor: 9.867

Review 7.  Fibroblast growth factors in cancer: therapeutic possibilities.

Authors:  Michael Jeffers; William J LaRochelle; Henri S Lichenstein
Journal:  Expert Opin Ther Targets       Date:  2002-08       Impact factor: 6.902

8.  Expression of extracellular matrix metalloprotease inducer in laryngeal squamous cell carcinoma.

Authors:  Eben L Rosenthal; Satya Shreenivas; Glenn E Peters; William E Grizzle; Renee Desmond; Candece L Gladson
Journal:  Laryngoscope       Date:  2003-08       Impact factor: 3.325

9.  EMMPRIN-mediated MMP regulation in tumor and endothelial cells.

Authors:  Stéphanie Caudroy; Myriam Polette; Béatrice Nawrocki-Raby; Jian Cao; Bryan P Toole; Stanley Zucker; Philippe Birembaut
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

10.  FGFR2 mutations are rare across histologic subtypes of ovarian cancer.

Authors:  Sara A Byron; Michael G Gartside; Candice L Wellens; Paul J Goodfellow; Michael J Birrer; Ian G Campbell; Pamela M Pollock
Journal:  Gynecol Oncol       Date:  2010-01-27       Impact factor: 5.482

View more
  11 in total

1.  The Ah receptor regulates growth factor expression in head and neck squamous cell carcinoma cell lines.

Authors:  Kaarthik John; Tejas S Lahoti; Kelly Wagner; Jarod M Hughes; Gary H Perdew
Journal:  Mol Carcinog       Date:  2013-04-27       Impact factor: 4.784

2.  Inhibition of fibroblasts reduced head and neck cancer growth by targeting fibroblast growth factor receptor.

Authors:  Larissa Sweeny; Zhiyong Liu; William Lancaster; Justin Hart; Yolanda E Hartman; Eben L Rosenthal
Journal:  Laryngoscope       Date:  2012-03-27       Impact factor: 3.325

3.  Dynamic contrast-enhanced MRI evaluates the early response of human head and neck tumor xenografts following anti-EMMPRIN therapy with cisplatin or irradiation.

Authors:  Hyunki Kim; Yolanda E Hartman; Guihua Zhai; Thomas K Chung; Melissa L Korb; Timothy M Beasley; Tong Zhou; Eben L Rosenthal
Journal:  J Magn Reson Imaging       Date:  2015-02-20       Impact factor: 4.813

4.  CD147 and AGR2 expression promote cellular proliferation and metastasis of head and neck squamous cell carcinoma.

Authors:  Larissa Sweeny; Zhiyong Liu; Benjamin D Bush; Yolanda Hartman; Tong Zhou; Eben L Rosenthal
Journal:  Exp Cell Res       Date:  2012-05-30       Impact factor: 3.905

Review 5.  The wound healing, chronic fibrosis, and cancer progression triad.

Authors:  Brad Rybinski; Janusz Franco-Barraza; Edna Cukierman
Journal:  Physiol Genomics       Date:  2014-02-11       Impact factor: 3.107

6.  EMMPRIN/CD147 up-regulates urokinase-type plasminogen activator: implications in oral tumor progression.

Authors:  Géraldine Lescaille; Suzanne Menashi; Bénédicte Cavelier-Balloy; Farah Khayati; Cathy Quemener; Marie Pierre Podgorniak; Benyoussef Naïmi; Fabien Calvo; Céleste Lebbe; Samia Mourah
Journal:  BMC Cancer       Date:  2012-03-23       Impact factor: 4.430

Review 7.  The biological function and clinical utilization of CD147 in human diseases: a review of the current scientific literature.

Authors:  Lijuan Xiong; Carl K Edwards; Lijun Zhou
Journal:  Int J Mol Sci       Date:  2014-09-29       Impact factor: 5.923

8.  The tumor microenvironment contribution to development, growth, invasion and metastasis of head and neck squamous cell carcinomas.

Authors:  Sittichai Koontongkaew
Journal:  J Cancer       Date:  2013-01-01       Impact factor: 4.207

9.  Extracellular matrix metalloproteinase inducer (EMMPRIN) expression correlates positively with active angiogenesis and negatively with basic fibroblast growth factor expression in epithelial ovarian cancer.

Authors:  Sebastian Szubert; Dariusz Szpurek; Rafal Moszynski; Michal Nowicki; Andrzej Frankowski; Stefan Sajdak; Slawomir Michalak
Journal:  J Cancer Res Clin Oncol       Date:  2013-12-28       Impact factor: 4.553

Review 10.  A Network Map of FGF-1/FGFR Signaling System.

Authors:  Rajesh Raju; Shyam Mohan Palapetta; Varot K Sandhya; Apeksha Sahu; Abbas Alipoor; Lavanya Balakrishnan; Jayshree Advani; Bijesh George; K Ramachandra Kini; N P Geetha; H S Prakash; T S Keshava Prasad; Yu-Jung Chang; Linyi Chen; Akhilesh Pandey; Harsha Gowda
Journal:  J Signal Transduct       Date:  2014-04-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.